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The answer is (hold your breath)—not yet. But the evidence continues to accumulate forthe efficacy of endobronchial ultrasound (EBUS) and esophageal ultrasound fine
needle aspiration (FNA) approaches to mediastinal staging in non-small cell lung cancer
(NSCLC). In this issue of the Journal, Ernst and colleagues1 present a provocative study
of the diagnostic yield of EBUS-FNA versus mediastinoscopy in patients with suspected
or confirmed NSCLC. Patients underwent both procedures either concurrently or within a
1 week interval. Results were compared with surgical mediastinal lymph node dissection
at the time of lung resection. EBUS-FNA overall had a higher diagnostic yield than
mediastinoscopy in 66 patients. The majority of the differences observed between the two
modalities appeared to occur in sampling station seven. The authors conclude that
EBUS-FNA may be preferred in the histologic sampling of paratracheal and subcarinal
mediastinal adenopathy because the diagnostic yield can surpass mediastinoscopy.
What’s that you say? Mediastinoscopy has long been the gold standard in medias-
tinal staging, with its origins in the pre-CT and positron emission tomography (PET) scan
days. Historically, it has been the key modality for accurate prelung resection staging of
the mediastinum, and continues to be used routinely in many centers for all patients with
suspected or confirmed NSCLC. The arrival of endoscopic staging approaches as new kids
on the block has evoked visceral responses from many in the surgical old guard. Their
promise as useful tools however continues to be demonstrated, leading to adoption by
pulmonologists, gastroenterologists, and thoracic surgeons alike.
Will endoscopic mediastinal staging replace mediastinoscopy? Although it may well
find a place as the first line approach, clearly more data is needed. Some cautionary notes
remain. The data we have seen so far here and from others2 is really by the innovaters in
endoscopic staging, and may not be representative of real world results. Our own
experience using endoscopic staging as a front-line approach suggests that false-negatives
revealed by subsequent mediastinoscopy do occur. That being said, results from medias-
tinoscopy itself are not universally equal. At present, operator “dose” is clearly variable
for both endoscopic staging and mediastinoscopy, as are the subsequent results. Sorting
out where and when endoscopic staging works and doesn’t work best is clearly the next
step.
One area of concern in interpreting results from the current study is the relatively
poor results in the mediastinoscopy arm with respect to sensitivity and negative predictive
value, particularly in the context of lymph nodes 10 mm. This does not compare well
with other results available in the literature, specifically the 5.5% false negative rate of
Lemaire et al.;3 or the 93.6% diagnostic rate found in Hammoud et al.4 These are both
large retrospective series with over 2000 patients, and represent the typical results in large
volume thoracic surgical centers performing routine mediastinoscopy. The reported results
in the current paper of a sensitivity of 68% and a negative predictive value of 59% do not
compare well with what one would expect based on these and other reports. This is
critically important in the context of conclusions about the role of endoscopic staging in
management algorithms, particularly in head-to-head comparisons with mediastinoscopy.
The issue remains unsettled. These and other data are clearly thought provoking
however, and suggest enough of a possible advantage (or at least equivalence) of
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EBUS-FNA to justify larger, confirmatory studies. Although
the complication rates of mediastinoscopy in major centers
remains low, it is certainly not zero. From a minimally
invasive standpoint, endoscopic staging offers obvious ad-
vantages to the patient as a front-line approach. A random-
ization between the two groups will be the only way to clearly
settle the issue, but the will to carry out such a study with the
required patient numbers may not be there to get it done.
Other issues complicate the picture, such as the emerging low
rate of occult N2 disease for clinical T1N0 NSCLC in the
modern CT/PET era. How endoscopic mediastinal staging
performs in various NSCLC patient subgroups remains an
unanswered question. Clearly however, the idea of a mini-
mally invasive pathway for early stage NSCLC involving
endoscopic mediastinal staging and video assisted thoracic
surgery lobectomy is appealing. Lung cancer physicians ea-
gerly await data demonstrating equivalent oncologic out-
comes for such algorithms with more traditional approaches.
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